Received: 30 October 2020
Accepted: 5 January 2021
First Online: 13 January 2021
Ethics approval and consent to participate
: This study used anonymized data. Because the study used anonymized information, institutional ethics approval and informed consent were not required, in accordance with Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan.
: Not applicable.
: Dr. Inada received personal fees from Dainippon Sumitomo Pharma, Eisai, Eli Lilly Japan, Janssen pharmaceutical, Meiji-Seika Pharmaceutical, Mochida, MSD, Novartis, Otsuka Pharmaceutical, Shionogi, Tanabe-Mitsubishi Pharma and Yoshitomi Yakuhin, and grants from MSD, outside the submitted work. Dr. Enomoto has no conflict of interest to disclose. Mr. Yamato and Mr. Marumoto are employed by Takeda Pharmaceutical Company Limited. Dr. Takeshima received lecture fees from Daiichi Sankyo Company outside the submitted work. Prof Mishima received speaker’s honoraria from Eisai Co., Ltd., MSD Inc., Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation (Yoshitomiyakuhin Corporation) and Janssen Pharmaceutical, consulting fee from Taisho Pharmaceutical Co., Ltd., research support from the Japanese Ministry of Health, Labour and Welfare (H29-Seishin-Ippan-001, 19GC1012), the Japanese Ministry of Education, Science, and Technology and the National Center of Neurology and Psychiatry (Intramural Research Grant for Neurological and Psychiatric Disorders), and research grants from Eisai Co., Ltd., Nobelpharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd.